Arrowhead Pharmaceuticals Stock Price and Value Analysis

Should you buy Arrowhead Pharmaceuticals stock? (NasdaqGS:ARWR). Let's see how it does in our automated value investing analysis system.

  • This company is not making money.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company pays no dividend.

Inside the ARWR Numbers

ARWR Price
(Arrowhead Pharmaceuticals stock price per share)
[?] PE Ratio versus Sector 2139% higher than other Healthcare stocks
[?] PE Ratio versus Industry 685% higher than other Biotechnology stocks
[?] Cash Yield -2.00%
[?] Free Cash Flow Jitter 234%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 3,937,678 shares shorted. With 103,166,750 shares available for purchase and an average trading volume over the past 10 trading days of 750,280, it would take at least 5.248 days for all of the short holders to cover their shorts.

Is Arrowhead Pharmaceuticals Stock on Sale?

Based on our analysis, we believe that you should not buy Arrowhead Pharmaceuticals right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ARWR Stock?

Does Arrowhead Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.